Want to join the conversation?
$BIIB said Bioverativ will continue commercialization of ELOCTATE and ALPROLIX, indicated for treatment of hemophilia A and B under $BIIB's existing collaboration agreement with Swedish Orphan Biovitrum AB. After spin-off, Bioverativ expects to continue development of ELOCTATE and ALPROLIX. Bioverativ plans to trade under "BIVV" ticker.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!